Abstract

The Cancer Cell Signaling (SIG) program seeks to stimulate and facilitate fundamental research in mechanisms of cell signaling. SIG does this through new faculty recruitment, and promoting program interactions, collaborations, and information sharing. Co-leaders of the program David L. Brautigan and Kimberly A. Kelly decide on program membership status in consultation with senior leadership, and act as advisors for faculty and mentors for fellows and students by encouraging team-based research projects, and participating in the weekly Cancer Center seminar series, student journal clubs, and programmatic research conferences. SIG is comprised of 25 members from 15 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 2 associate members. The high quality science by SIG has resulted in over 318 publications over the past 5 years, with 43% inter- programmatic and 10% intra-programmatic co-authorships. Total extramural funding for the Program exceeds $8.8M, including over $3.9 million from the National Cancer Institute (NCI) and $3.8M from other NIH institutes. Members of SIG are a valuable resource and highly collaborative, supporting activities throughout the Cancer Center, as one of the cornerstones of the UVA Cancer Center research enterprise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-26
Application #
9209276
Study Section
Special Emphasis Panel (NCI (E3)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
26
Fiscal Year
2017
Total Cost
$27,633
Indirect Cost
$10,144

  Institution

Name
University of Virginia
Department
Type
Domestic Higher Education
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904

  Publications

Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257

Showing the most recent 10 out of 539 publications